George Demetri, M.D.
Professor of Medicine, Harvard Medical School
Director, Center for Sarcoma and Bone Oncology
Dana-Faber Cancer Institute
Dr. Demetri is a professor of medicine at Harvard Medical School and is director of the Center for Sarcoma and Bone Oncology at Dana-Farber Cancer Institute (DFCI). He is a pioneer in the development of imatinib (Gleevec), one of the first targeted anticancer therapies for chronic myeloid leukemia and other hematologic malignancies and for gastrointestinal stromal tumors (GISTs). His work contributed to the FDA approval of several other “smart drugs” for cancer treatment, including sunitinib in GIST, and, most recently, pazopanib for other sarcomas.
Dr. Demetri has designed and implemented a world-renowned clinical research center focused on the treatment of sarcomas, and his team is at the cutting edge of developing personalized cancer therapeutics for specific subtypes of sarcomas.
He has received many awards, including a Focused Giving Program Award from the Johnson and Johnson Foundation, the Emil J. Freireich Award in Clinical Cancer Research from MD Anderson Cancer Center, the Alexander Bodini Foundation Prize for Scientific Excellence in Medicine, and the Hope Funds for Cancer Research Award for Developmental Therapeutics.
He received his medical degree at Stanford University School of Medicine, completed a residency in internal medicine at the University of Washington Hospitals, and completed a fellowship in hematology and oncology at DFCI.